Cell Biotech Q1 2026: Sales Up, OP +134%, Potential for Dividend and Buyback

Consolidated sales 14,597 million won (+30% YoY), operating profit 3,187 million (+134%), parent net profit 5,352 million (+159%)
Cash and cash equivalents 26.7 billion won, short-term financial instruments 67.9 billion won; strong liquidity
Debt-to-equity ratio 7.71%, very solid financial structure
Colorectal cancer drug PP-P8 phase 1 clinical trial IND approved (Jan 2025) and patient recruitment underway
31st AGM approved capital reserve reduction to fund share buyback and dividends
Treasury shares 27.19% (2.556 million shares), room for future shareholder returns